Close

Press Releases

Lilly, AACE Mark 10th Anniversary Of Hurricane Katrina With Reminder Of “My Diabetes Emergency Plan” Checklist

  The checklist, now in its ninth year, is a direct result of post-Katrina learnings ,For Sherry Martin, M.D., starting her new job at Eli Lilly and Company (NYSE: LLY) in August 2005 was stressful enough. ...

U.S. District Court Rules In Lilly’s Favor On Alimta Vitamin Regimen Patent

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). ...

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant...

Jardiance® Demonstrated Cardiovascular (CV) Risk Reduction In People With Type 2 Diabetes At High Risk For CV Events

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes...

Lilly’s Humalog® 200 Units/ML KwikPen® Now Available In U.S. Pharmacies

First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S.,...

U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with previously untreated advanced melanoma. The...

Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.

Company enters into a collaboration agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute as part of the I-O RPM program "Immunotherapy is rapidly evolving and has an enormous promise...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »